Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury | MicrobiomeTrials← Back to trialsNCT07518303
Nafamostat Mesylate Versus Regional Citrate Anticoagulation for Continuous Renal Replacement Therapy in Sepsis-Associated Acute Kidney Injury
RecruitingPHASE4INTERVENTIONAL
Trial Details
Start: 2026-06-10Est. Completion: 2028-06-10
Enrollment target: 1,162 participants Other microbiome trials you might be interested in
Heart Failure, CongestiveRenal Failure Acute ChronicLiver CirrhosisSepsisEdema, PulmonaryEstablish a Real-time Focused Ultrasound Examination Protocol for Routine Assessment of Hospitalized PatientsEdema
This research project aims to establish a real-time focused ultrasound examination protocol for routine assessment of ho…
Taipei, TaiwanEst. completion Apr 17, 2026
Elderly PatientsCancer SurgeryHypothermia, Accidental
Targeted Temperature Management
Delayed Neurocognitive Recovery
With aging population, more older patients will receive major surgery for cancer. Older patients are at increased risk o…
Beijing, ChinaEst. completion Oct 2028
Clostridia Difficile ColitisClostridium; Sepsis
A new medication, Bezlotoxumab, has been approved for treatment of recurrent Clostridium difficile diarrhea by the U.S. …
Columbus, United StatesCompleted May 23, 2022